Buy stock quote BLRX, at $2.86 with a $5, 8 month target, BioLineRx Ltd. BioLineRx Ltd. has license agreements with Genoscience; Compugen Ltd.; RFS Pharma; Yissum and University of Genoa, Italy; Gestion Univalor, Limited Partnership; and Ikaria. The company was founded in 2003 and is headquartered in Jerusalem, Israel.

bIOLINERX, LTD. (BLRX)

 inShare1

+Follow 

Check out top analysts' recommendation for BLRX

Get a 1-Month Free Trial

Last closing price (Jan 27 4:00 EDT):

2.86 (-4.35%) ? 

Return to date (1m/3m/6m/12m):

4.00% ? 

Consensus price target (1m/3m/6m/12m):

N/A

 ? 

Buy/Sell Mix (1m/3m/6m/12m):

N/A

 ? 

Description:

BioLineRx Ltd., a clinical stage biopharmaceutical development company, engages in identifying, in-licensing, and developing therapeutic candidates. The company’s development pipeline consists of six clinical-stage therapeutic candidates, including BL-1020, which is in Phase II/III clarity trial to enhance cognitive function in schizophrenia patients; BL-1040, a novel polymer solution that is under pivotal CE-Mark registration trial for use in the prevention of pathological cardiac remodeling following a myocardial infarction; and BL-5010, a medical device, which has completed Phase I/II clinical trials for the non-surgical removal of skin lesions. Its development pipeline also includes BL-1021 that is in Phase Ia clinical trial for the treatment of neuropathic pain, or pain that results from damage to nerve fibers; BL-7040, which is in Phase II clinical trial for the treatment of inflammatory bowel disease; and BL-8040, a peptide that has completed Phase I/II clinical trial for the treatment of acute myeloid leukemia and other hematological cancers. The company also has six products in various pre-clinical development stages for indications, such as central nervous system diseases, infectious diseases, cardiovascular, and autoimmune diseases. In addition, it operates a biotechnology incubator to evaluate therapeutic candidates BioLineRx Ltd. has license agreements with Genoscience; Compugen Ltd.; RFS Pharma; Yissum and University of Genoa, Italy; Gestion Univalor, Limited Partnership; and Ikaria. The company was founded in 2003 and is headquartered in Jerusalem, Israel. (collapse)

Sector:

N/A

Industry:

N/A

Open and Closed  Open Only  Closed Only  ? 

Analyst?	Research Firm?	Signal?	Signal Date?	Initial Price?	Price Target?	Closing Date?	Return?
Charles Graham	Unaffiliated	Buy	Oct 05, '13	2.66	5.00	Oct 05, '14	7.52%
Mesut Dogan	Unaffiliated	Buy	Sep 20, '13	2.25	5.00	Mar 20, '14	27.11%
Ram Selvaraju	Aegis Capital	Buy	Sep 09, '13	2.30		Sep 09, '14	24.35%